Publication & Citation Trends
Publications
11 total
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts
Cited by 122
OpenAlex
AZD 5438 , a potent oral inhibitor of cyclin-dependent kinases 1 , 2 , and 9 , leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts
Cited by 13
Semantic Scholar
Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors PDF
Cited by 30
OpenAlex
The cellular phenotype of AZ703, a novel selective imidazo[1,2-<i>a</i>]pyridine cyclin-dependent kinase inhibitor PDF
Cited by 48
OpenAlex
Imidazo[1,2- a ]pyridines. Part 2 : SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors PDF
Cited by 113
OpenAlex
Imidazo[1,2- b ]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors PDF
Cited by 73
OpenAlex
Imidazo[1,2‐a]pyridines. Part 2. SAR and Optimization of a Potent and Selective Class of Cyclin‐Dependent Kinase Inhibitors.
Cited by 0
OpenAlex
Research Topics
Cancer-related Molecular Pathways
(8)
Advanced Breast Cancer Therapies
(7)
Microtubule and mitosis dynamics
(5)
Synthesis and Reactivity of Heterocycles
(4)
Cancer therapeutics and mechanisms
(2)
Affiliations
AstraZeneca (United Kingdom)